X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AstraZeneca will receive an exclusive license to develop and commercialize ECC5004, a small molecule GLP-1 receptor agonist, for the potential treatment of obesity, type-2 diabetes and other comorbidities, in all territories except China.
Lead Product(s): ECC5004
Therapeutic Area: Nutrition and Weight Loss Product Name: ECC5004
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $2,010.0 million Upfront Cash: $185.0 million
Deal Type: Licensing Agreement November 09, 2023
Details:
The proceeds will support the development of Eccogene’s clinical-stage programs including Phase I trial of ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and the Phase I trial of ECC4703, a THRb full agonist for NASH and lipid disorders.
Lead Product(s): ECC5004
Therapeutic Area: Endocrinology Product Name: ECC5004
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: New Alliance Capital
Deal Size: $25.1 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 12, 2023
Details:
ECC4703 was discovered from Eccogene's internal drug discovery platform. It is a β-selective, liver targeting THR full agonist. ECC4703 has demonstrated superiority in pre-clinical studies over partial agonist MGL-3196.
Lead Product(s): ECC4703
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ECC4703
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
The trial is a Phase 1, randomized, double-blind, placebo-controlled, sequential single- and multiple ascending dose clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics of ECC0509 in healthy volunteers.
Lead Product(s): ECC0509
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ECC0509
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
